clinical trial · NCT07187115
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Atrial Fibrillation (AF)Persistant Atrial FibrillationFARAPOINT Pulsed Field Ablation SystemOptiMap System (non-ablative)FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
brief summary
The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).
started
Nov 7, 2025
primary completion
Jul 1, 2028
completion
Dec 1, 2030
last updated
Mar 31, 2026
official title
A Global Randomized Trial Comparing Pulsed Field Ablation of Pulmonary Veins Plus Extra-PV Sources Utilizing Electrographic Flow Mapping Versus Pulmonary Veins Plus Posterior Wall in Persistent Atrial Fibrillation Patients.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol